CYTOSORBENTS CORP (CTSO) Stock News
NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD
CTSO Latest News, Press Relases and Analysis
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit...
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and...
CytoSorbents Announces Rights Offering
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024...
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller ...
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
CytoSorbents' Preliminary Unaudited Q4 2024 Product Revenue Increased 22-25% From A Year Ago With Product Gross Margins Of ~70% ...
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
CytoSorbents Rights Offering Begins
To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco....
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents Announces Rights Offering
Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions...
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor...
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in...